drugset / Trial / NCT06480630

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

NCT06480630

Phase 2 Not yet recruiting 39 enrolled Anhui Provincial Hospital
NaSingle-groupOpen-labelPrevention

Summary

Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.

Timeline

Start
2024-07-01
Primary completion
2026-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Basiliximab Monoclonal antibody